These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 2226434

  • 21. Thermodynamics of substrates and reversible inhibitors binding to the active site cleft of human alpha-thrombin.
    De Cristofaro R, Landolfi R.
    J Mol Biol; 1994 Jun 17; 239(4):569-77. PubMed ID: 8006969
    [Abstract] [Full Text] [Related]

  • 22. The crystal structures of human alpha-thrombin complexed with active site-directed diamino benzo[b]thiophene derivatives: a binding mode for a structurally novel class of inhibitors.
    Chirgadze NY, Sall DJ, Briggs SL, Clawson DK, Zhang M, Smith GF, Schevitz RW.
    Protein Sci; 2000 Jan 17; 9(1):29-36. PubMed ID: 10739244
    [Abstract] [Full Text] [Related]

  • 23. Comparison of the structures of the cyclotheonamide A complexes of human alpha-thrombin and bovine beta-trypsin.
    Ganesh V, Lee AY, Clardy J, Tulinsky A.
    Protein Sci; 1996 May 17; 5(5):825-35. PubMed ID: 8732754
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Crystal structure of the complex of human alpha-thrombin and nonhydrolyzable bifunctional inhibitors, hirutonin-2 and hirutonin-6.
    Zdanov A, Wu S, DiMaio J, Konishi Y, Li Y, Wu X, Edwards BF, Martin PD, Cygler M.
    Proteins; 1993 Nov 17; 17(3):252-65. PubMed ID: 8272424
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. 1-Aminoisoquinoline as benzamidine isoster in the design and synthesis of orally active thrombin inhibitors.
    Rewinkel JB, Lucas H, van Galen PJ, Noach AB, van Dinther TG, Rood AM, Jenneboer AJ, van Boeckel CA.
    Bioorg Med Chem Lett; 1999 Mar 08; 9(5):685-90. PubMed ID: 10201829
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Role of thrombin exosites in inhibition by heparin cofactor II.
    Rogers SJ, Pratt CW, Whinna HC, Church FC.
    J Biol Chem; 1992 Feb 25; 267(6):3613-7. PubMed ID: 1740413
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Influence of structural variations in peptidomimetic 4-amidinophenylalanine-derived thrombin inhibitors on plasma clearance and biliary excretion in rats.
    Hauptmann J, Steinmetzer T, Vieweg H, Wikström P, Stürzebecher J.
    Pharm Res; 2002 Jul 25; 19(7):1027-33. PubMed ID: 12180535
    [Abstract] [Full Text] [Related]

  • 37. Enzyme flexibility, solvent and 'weak' interactions characterize thrombin-ligand interactions: implications for drug design.
    Engh RA, Brandstetter H, Sucher G, Eichinger A, Baumann U, Bode W, Huber R, Poll T, Rudolph R, von der Saal W.
    Structure; 1996 Nov 15; 4(11):1353-62. PubMed ID: 8939759
    [Abstract] [Full Text] [Related]

  • 38. Comparative molecular modeling analysis of-5-amidinoindole and benzamidine binding to thrombin and trypsin: specific H-bond formation contributes to high 5-amidinoindole potency and selectivity for thrombin and factor Xa.
    Zhou Y, Johnson ME.
    J Mol Recognit; 1999 Nov 15; 12(4):235-41. PubMed ID: 10440994
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.